BACKGROUND:

The leadless pacemaker has emerged as a promising alternative for patients requiring artificial cardiac stimulation. Advanced atrioventricular block (AVB) is the primary indication for leadless pacemaker (LP) implantation in patients who have undergone transcatheter aortic valve replacement (TAVR), yet its benefits remain uncertain. This study aimed to assess the efficacy and safety of LPin post-TAVR patients.

METHODS:

PubMed, Embase, and Cochrane databases were searched for studies evaluating the implantation of leadless pacemakers in post-TAVR patients. Statistical analysis was performed using R version 4.3.2.

RESULTS:

We included six studies comprising 109 patients, with a mean age of 82 ± 3.21 years, of whom 52% (57 patients) were male. AVB was the primary indication in 55% of cases. Post-procedure complications occurred in 2.32% of patients (95% CI: 0.00 to 8.05%) and heart failure re-hospitalizations in 6.58% (95% CI: 0.00 to 18.00%). The average hospital stay was 9.33 days (95% CI: 8.64 to 10.03), and the mean procedure time was 40.77 minutes (95% CI: 22.32 to 59.23). All-cause mortality rate was 7.20% (95% CI: 0.18 to 14.22%).

CONCLUSION:

Leadless pacemaker implantation is a feasible option for post-TAVR patients. In terms of safety, outcomes appear to be comparable to data from traditional permanent pacemaker implantation. Additional randomized controlled trials are needed to further explore this issue.